Dr Reddy's Laboratories (DRL), the second largest pharma company in India, is facing new patent infringement lawsuit by AMRI (Albany Molecular Research, Inc) for infringement of AMRI's US Patent No 7,390,906 in the US District Court in New Jersey. This legal action relates to generic versions of sanofi-aventis's Allegra and AllegraD drug products.

"We believe that this patent infringement filing strengthens our litigation strategy on Allegra, AllegraD-12, and AllegraD-24 against these generic drug companies in the United States and other jurisdictions. AMRI remains committed to vigorously protecting and enforcing its intellectual property," said AMRI chairman, president and CEO Thomas E D'Ambra.

In November 2008, AMRI announced a settlement regarding two US patent infringement litigations involving Allegra and AllegraD-12 to allow sanofi-aventis US LLC to sublicense patents related to Allegra and AllegraD-12 to Teva Pharmaceuticals, USA, Inc. and Barr Laboratories, Inc. in the United States for which AMRI receives royalties on the sale of products containing fexofenadine hydrochloride (the generic name for the active ingredient in Allegra) and products containing fexofenadine hydrochloride and pseudoephedrine hydrochloride (generic AllegraD-12) by Teva Pharmaceuticals, USA, Inc and Barr Laboratories, Inc through 2015, along with additional considerations.

AMRI provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies.